首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1750227

癌症的γδT細胞療法的全球市場:市場趨勢，技術平台，臨床試驗預測(2031年)

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

出版日期: 2025年06月01日 | 出版商:

KuicK Research | 英文 210 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球癌症的γδT細胞療市場趨勢，技術平台，臨床試驗預測(2031年)報告的結論

臨床試驗中的γδT細胞抗癌療法：>25+種療法
最高研發階段：II/III期
截至2025年6月，尚無γδT細胞療法實現商業化
美國和中國γδT細胞療法臨床試驗占主導地位：20+種療法
γδT細胞療法臨床試驗洞察：依公司、國家、適應症、階段劃分
γδT細胞療法技術平台公司洞察：15+個平台
以適應症劃分的γδT細胞療法市場潛力

適應性γδT細胞 (Yδ)免疫療法是一種新型免疫療法，利用獨特的T細胞亞群來辨識並摧毀癌細胞。典型的αβ（aB）T細胞辨識由主要組織相容性複合體（MHC）分子呈現的抗原，而YδT細胞則以MHC非依賴的方式被壓力誘導的配體和磷酸化抗原活化。這使得它們能夠檢測並針對多種腫瘤，包括那些傳統免疫警戒機制未針對的腫瘤。 YδT細胞兼具先天免疫和適應性免疫的特性，並具有即時應答和免疫記憶的能力，使其成為現成的過繼細胞療法的理想候選者。

在癌症治療中，YδT細胞因其無需技術難度高且成本高昂的腫瘤特異性抗原或基因改造即可摧毀惡性細胞的潛力而備受關注。其固有的細胞毒性，加上可以使用同種異體細胞（來自健康捐贈者）的可能性，為大規模生產和廉價治療提供了途徑。迄今為止，大多數臨床研發都集中在血液系統惡性腫瘤領域，該領域前景廣闊。 Yδ T 細胞可以侵入骨髓和其他淋巴器官，並透過釋放細胞激素、直接細胞毒性和改變腫瘤微環境來影響腫瘤。

迫切需要新的癌症療法，尤其是像急性骨髓性白血病 (AML) 這樣的血液系統癌症，這類癌症容易復發或對常規療法產生抗藥性。對於緩解後復發或有殘留疾病 (MRD) 的患者，治療選擇有限，預後通常較差。 Yδ T 細胞療法具有獨特的優勢，可以填補這一空白，它提供了一種可能有效、安全且易於獲取的現成產品，並且不存在自體 T 細胞療法的後勤問題，例如生產暫停和患者個體差異。

TC Biopharm 在該領域的臨床開發中處於領先地位。該公司最先進的候選產品 OmnImmune（原名 TCB-002）目前正在進行針對急性髓性白血病 (AML) 的關鍵性 II/III 期臨床試驗。 OmnImmune 是一種同種異體 Yδ T 細胞療法，旨在快速靶向並摧毀癌細胞，同時避免對正常組織的損害。該臨床計畫是全球 Yδ T 細胞產品線中最先進的計畫之一，彰顯了 TC Biopharm 在該領域新興的領導地位。除了 OmnImmune，該公司還有多個 Yδ T 細胞候選藥物正在開發中，用於治療各種癌症。

TC Biopharm 近期最重要的進展之一是其 TCB008 候選藥物的開發，該藥物目前正在進行 II 期 ACHIEVE 試驗。 2025 年 6 月，該公司報告稱，B 組首例患者（先前復發且可檢測到微小殘留疾病 (MRD)）在接受兩次給藥後實現了完全分子緩解 (CRT)。治療後檢測不到NPM1轉錄本顯示療效顯著且持久，展現了TCB008作為血液系統癌症緩解後治療的潛力。這項結果凸顯了YδT細胞強大的標靶免疫功能，並證明了其作為一種新型治療策略的作用。

在全球範圍內，大多數對YδT細胞的研究仍停留在血液系統惡性腫瘤領域，針對實體腫瘤的項目較少。部分原因是實體瘤利用更複雜的微環境和免疫逃脫機制。然而，人們正在嘗試將YδT細胞療法應用於這些更具課題性的治療環境。從地區來看，美國公司在YδT細胞療法市場佔據主導地位，其次是越來越多的中國公司。這些地區在細胞療法設施和技術方面投入了大量資金，促進了該療法從實驗室到臨床的快速轉變。

展望未來，YδT細胞療法前景光明，但其在實體腫瘤中的臨床驗證仍需持續。生產和生物標記驅動策略的進步有望將YδT細胞的應用擴展到更多癌症類型。在TC Biopharm等領導企業的引領下，該領域可望為腫瘤學領域尚未滿足的重大需求提供改變生命的治療方案。

Gamma Delta T Cell Therapies In Clinical Trials: > 25 Therapies
Highest Phase Of Development: Phase II/III
As Of June'2025 No Gamma Delta T Cells Therapy Is Commercially Available
US & China Dominating Gamma Delta T Cell Therapies Clinical Trials Landscape: > 20 Therapies
Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
Gamma Delta T Cell Therapies Technology Platforms Insight By Company : > 15 Platforms
Gamma Delta T Cell Therapy Market Potential By Indications Based On Adoption Rates

Adoptive gamma delta (Yδ) T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aB) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, Yδ T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. Yδ T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies.

In cancer, Yδ T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Yδ T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor.

The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Yδ T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability.

TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic Yδ T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global Yδ T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other Yδ T cell candidates in development for various cancer indications.

One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of Yδ T cells and substantiates their role as a new therapeutic strategy.

Globally, most of the research studies on Yδ T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply Yδ T cell treatments to these more difficult contexts. Geographically, US-based players dominate the Yδ T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside.

Moving forward, the prospects for Yδ T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of Yδ T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain.

1. Introduction To Gamma Delta T Cell Therapy

1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. Role of Gamma Delta T Cells in Cancer

2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview

4.1 Current Market Scenario
4.2 Future R&D & Commercial Opportunities
4.3 Market Potential of Gamma Delta T Cell Therapy Market
4.4 Technology Platforms For Gamma Delta T Cell Therapy
4.5 Favorable Market Growth Parameters
4.6 Key Challenges To Overcome For Future Growth

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview

5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III

7. Gamma Delta T Cell Therapy In Leukemia

7.1 Ongoing Clinical Research & Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia

8. Gamma Delta T Cell Therapy In Lung Cancer

8.1 Ongoing Clinical Research & Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer

9. Gamma Delta T Cells In Breast Cancer

9.1 Ongoing Clinical Research & Development Trends
9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer

10.1 Ongoing Clinical Research & Development Trends
10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

11. Gamma Delta T Cells In Pancreatic Cancer

11.1 Ongoing Clinical Research & Development Trends
11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer

12. Gamma Delta T Cells In Lymphoma

12.1 Ongoing Clinical Research & Development Trends
12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma

13. Gamma Delta T Cell Therapy In Brain Tumors

13.1 Research & Development In Brain Tumors
13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors

14. Gamma Delta T Cell Therapy In Head & Neck Cancer

14.1 Research & Development In Head & Neck Cancer
14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer

15. Competitive Landscape

15.1 Acepodia
15.2 Adicet
15.3 Appia Bio
15.4 Cytomed Therapeutics
15.5 Century Therapeutics
15.6 Expression Therapeutics
15.7 Immatics
15.8 IN8bio
15.9 JY BioMed
15.10 Legend Biotech
15.11 Luminary Therapeutics
15.12 PhosphoGam
15.13 Takeda
15.14 TC Biopharm
15.15 ViGenCell

簡介目錄圖表

List of Figures

Figure 1-1: History Of T Cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: CAR T Cell Therapy Limitations
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions Of Gamma Delta T Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
Figure 2-5: Functional Advantages Of Yo T Cells for CAR T Cancer Therapy
Figure 2-6: CAR Yo T Cells - Mechanism of Action
Figure 4-1: Gamma Delta T Cell Therapy Market - Future Opportunities
Figure 4-2: Global - Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-3: Global - Gamma Delta T Cell Therapy Market Opportunity By 1% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-4: Global - Gamma Delta T Cell Therapy Market Opportunity By 2% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-5: Global - Gamma Delta T Cell Therapy Market Opportunity By 3% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-6: Global - Gamma Delta T Cell Therapy Market Opportunity By 4% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-7: Global - Gamma Delta T Cell Therapy Market Opportunity By 5% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-8: Global - Gamma Delta T Cell Therapy Market Opportunity By 6% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-9: Global - Gamma Delta T Cell Therapy Market Opportunity By 7% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-10: Global - Gamma Delta T Cell Therapy Market Opportunity By 8% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-11: Global - Gamma Delta T Cell Therapy Market Opportunity By 9% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-12: Global - Gamma Delta T Cell Therapy Market Opportunity By 10% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-13: IN8bio - DeltEx DRI Auto
Figure 4-14: Diamond AI - Prediction Engine
Figure 4-15: Diamond AI - Immune Surveillance
Figure 4-16: Acepodia - Antibody-Cell Conjugation
Figure 4-17: Lava Therapeutics - Gammabody Platform
Figure 4-18: Adicet Bio - Gamma Delta Cell Platform
Figure 4-19: ADI-001 - Gamma Delta Cell Therapy
Figure 4-20: Century Therapeutics - Allo-Evasion
Figure 4-21: ViGenCell - ViRanger Platform
Figure 4-22: Legend Biotech - CAR-Yo T Platform
Figure 4-23: Immatics - ACTallo(R) Manufacturing Process
Figure 4-24: Gamma Delta T Cell Platform - carxall
Figure 4-25: Proprietary Manufacturing & Cell Platform Process - Adicet Bio
Figure 4-26: CAR-Yo T Cell - CytoMed Therapeutics
Figure 4-27: iPSC-Yo NKT Cells - CytoMed Therapeutics
Figure 4-28: Luminary Therapeutics - TcBuster Benefits
Figure 4-29: SSC Cell Platform - Core Foundations
Figure 4-30: Acua Platform - Appia Bio
Figure 4-31: Gamma Delta T Cell Therapy Market Drivers & Opportunities
Figure 4-32: Gamma Delta T Cell Therapy Market Challenges & Restraints
Figure 5-1: Global - Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2025 Till 2031
Figure 5-2: Global - Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2025 Till 2031
Figure 5-3: Global - Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2025 Till 2031
Figure 5-4: Global - Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2025 Till 2031
Figure 5-5: Global - Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2025 Till 2031
Figure 7-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 7-2: CD33CART Phase 1/2 (NCT03971799) Study - Initiation & Completion Year
Figure 7-3: ACHIEVE (TCB008-001) Phase 2 (NCT05358808) Study - Initiation & Completion Year
Figure 7-4: ACHIEVE2 (TCB008-003) Phase 1 (NCT06463327) Study - Initiation & Completion Year
Figure 7-5: INB-100 Phase 1 (NCT03533816) Study - Initiation & Completion Year
Figure 7-6: Mechanism of Action of VY9/CD123 Bispecific Antibody
Figure 7-7: Global - Estimated Leukemia Cases, 2025-2031
Figure 7-8: US - Estimated Leukemia Cases, 2025-2031
Figure 7-9: Europe - Estimated Leukemia Cases, 2025-2031
Figure 7-10: China - Estimated Leukemia Cases, 2025-2031
Figure 7-11: Japan - Estimated Leukemia Cases, 2025-2031
Figure 8-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 8-2: DELTACEL-01 Phase 1 (NCT06069570) Study - Initiation & Completion Year
Figure 8-3: Global - Estimated Lung Cancer Cases, 2025-2031
Figure 8-4: US - Estimated Lung Cancer Cases, 2025-2031
Figure 8-5: Europe - Estimated Lung Cancer Cases, 2025-2031
Figure 8-6: China - Estimated Lung Cancer Cases, 2025-2031
Figure 8-7: Japan - Estimated Lung Cancer Cases, 2025-2031
Figure 9-1: Global - Estimated Breast Cancer Cases, 2025-2031
Figure 9-2: US - Estimated Breast Cancer Cases, 2025-2031
Figure 9-3: Europe - Estimated Breast Cancer Cases, 2025-2031
Figure 9-4: China - Estimated Breast Cancer Cases, 2025-2031
Figure 9-5: Japan - Estimated Breast Cancer Cases, 2025-2031
Figure 10-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 10-2: Mechanism Underlying B7-H3 Regulating Yo T Cells Killing Colon Cancer Cells
Figure 10-3: SGNEGFRd2-001 Phase I (NCT05983133) Study - Initiation & Completion Year
Figure 10-4: Global - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-5: US - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-6: Europe - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-7: China - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-8: Japan - Estimated Colorectal Cancer Cases, 2025-2031
Figure 11-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 11-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 11-3: Global - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-4: US - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-5: Europe - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-6: China - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-7: Japan - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 12-1: ACE1831 Phase I (NCT05653271) Study - Initiation & Completion Year
Figure 12-2: ADI-001 Phase I (NCT04735471) Study - Initiation & Completion Year
Figure 12-3: Global - Estimated Lymphoma Cases, 2025-2031
Figure 12-4: US - Estimated Lymphoma Cases, 2025-2031
Figure 12-5: Europe - Estimated Lymphoma Cases, 2025-2031
Figure 12-6: China - Estimated Lymphoma Cases, 2025-2031
Figure 12-7: Japan - Estimated Lymphoma Cases, 2025-2031
Figure 13-1: INB-400 Phase 1/2 (NCT05664243) Study - Initiation & Completion Year
Figure 13-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
Figure 13-3: UAB 1773 Phase 1 (NCT04165941) Study - Initiation & Completion Year
Figure 13-4: Global - Estimated Brain Cancer Cases, 2025-2031
Figure 13-5: US - Estimated Brain Tumor Cases, 2025-2031
Figure 13-6: Europe - Estimated Brain Tumor Cases, 2025-2031
Figure 13-7: China - Estimated Brain Tumor Cases, 2025-2031
Figure 13-8: Japan - Estimated Brain Tumor Cases, 2025-2031
Figure 14-1: Acepodia Biotech Clinical Pipeline Insight
Figure 14-2: Pfizer & Lava Therapeutics Collaboration
Figure 14-3: SGN-EGFRd2 Phase 1 (NCT05983133) Study - Initiation & Completion Year
Figure 14-4: Global - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-5: US - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-6: Europe - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-7: China - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-8: Japan - Estimated Head & Neck Cancer Cases, 2025-2031

List of Tables

Table 3-1: Ongoing Clinical Trials For Combination Of Gamma Delta T Cell Therapy
Table 7-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 8-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 9-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 10-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 11-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 12-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 13-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 14-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
Table 14-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

工程 T 細胞市場 - 全球產業規模、佔有率、趨勢、機會和預測（按類型、應用、最終用戶、地區和競爭細分，2020-2030 年）

人工 T 細胞市場：按類型、應用和最終用戶分類 - 全球預測 2025-2030

全球 T 細胞治療市場評估：按方式、治療類型、適應症、最終用戶、地區、機會、預測（2016-2030）

監管性 T 細胞療法市場 - 2023-2035 年全球產業規模、佔有率、趨勢、機會和預測，按類型、應用程式、最終用戶、地區、競爭細分

FAQ

癌症的γδT細胞療法的全球市場:市場趨勢，技術平台，臨床試驗預測(2031年)

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

目錄

第1章 γδT細胞療法的簡介

第2章癌症的γδT細胞所扮演的角色

第3章 γδT細胞療法能放的高度的並用策略

第4章 γδT細胞療法市場概要

第5章全球γδT細胞療法的臨床試驗概要

第6章世界γδT細胞療法臨床試驗的洞察，企業，國家，適應症，各相

第7章白血病的γδT細胞療法

第8章肺癌症的γδT細胞療法

第9章乳癌的γδT細胞

第10章大腸癌症的γδT細胞

第11章胰臟癌症的γδT細胞

第12章淋巴瘤的γδT細胞

第13章腦瘤的γδT細胞療法

第14章頭頸椎癌症的γδT細胞療法

第15章競爭情形